Journal
JOURNAL OF CLINICAL MICROBIOLOGY
Volume 49, Issue 10, Pages 3683-3686Publisher
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.01239-11
Keywords
-
Categories
Funding
- Fondo de Investigaciones Sanitarias (Ministerio de Sanidad y Consumo, Madrid, Spain) [FIS07/0551]
- Sociedad Espanola de Neumologia y Cirugia Toracica (SEPAR)
- Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica (SEIMC) for acquiring skills in pyrosequencing methods at the Health Protection Agency (Colindale, London, United Kingdom) [3/2006]
- Instituto de Salud Carlos III (Spain)
- AGAUR (Agencia de Gestio d'Ajuts Universitaris i de Recerca), Generalitat de Catalunya, Spain
Ask authors/readers for more resources
The aim of this study was to evaluate a pyrosequencing method for the detection of Mycobacterium tuberculosis isolates resistant to rifampin and isoniazid using both clinical strains and clinical samples, comparing the results with those of the Bactec 460TB and GenoType MTBDRplus assays. In comparison to Bactec 460TB as the gold standard, the sensitivity of pyrosequencing for detecting isoniazid and rifampin resistance was 76.9% and 97.2%, respectively, for clinical strains, and the specificity was 97.2 and 97.9%, respectively. For clinical specimens, the sensitivity and specificity for both drugs were 85.7% and 100%, respectively. The overall concordance between pyrosequencing and the GenoType MTBDRplus assay for clinical strains was 99.1%, and for clinical samples, it was 98.2%. Pyrosequencing is a valuable tool for rifampin and isoniazid resistance detection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
